• Home
  • Journal
  • Public Companies
  • Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

EWING, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA).   
Moderated Poster PresentationThe poster entitled “Comparison of Pharmacokinetic Profiles of Testosterone Therapy Products in Relation to Diurnal Variation of Serum Testosterone Levels” will be presented by Alexander Pastuszak, MD, PhD, University of Utah School of Medicine, Salt Lake City, Utah. The submission was among a select group of key abstracts awarded the distinction of a moderated poster presentation.The goal of the study was to review the pharmacokinetic (PK) profiles of serum testosterone in different exogenous testosterone formulations and compare these PK profiles with daily variations in endogenous serum testosterone levels. A review of daily testosterone variation studies in adult men was conducted followed by literature searches and product prescribing information review of a variety of testosterone therapies. Routes of administration considered were subcutaneous testosterone enanthate (XYOSTED®), intramuscular testosterone, topical testosterone gel, topical testosterone solution, subdermal pellets, nasal testosterone gel, oral testosterone and the testosterone buccal system.Date: Saturday, October 26, 2019 – 1:50 p.m.
Session: Moderated Poster Session: Androgens
Session Time: 1:30 p.m. – 3:00 p.m. Eastern Time
Location: OMNI Nashville Hotel, Nashville, Tennessee 
e-Poster PresentationThe poster entitled “Testosterone Patient Journey Analysis” will be presented by Irwin Goldstein, MD, San Diego Sexual Medicine, San Diego, California.Male hypogonadism is a clinical syndrome resultant of pathological failure within the hypothalamic-pituitary-testicular axis that normally produces physiological required concentrations of testosterone.  Erectile dysfunction, fatigue/lethargy, depressive symptoms, and decreased energy and libido are common symptoms associated with decreased testosterone concentrations.  Testosterone therapy is clinically recommended in men with hypogonadism. An analysis of the hypogonadal patient journey was conducted to explore the initial symptoms, impact of initial treatment, and patients’ concerns and current mindset about testosterone replacement therapy.Date: Saturday, October 26, 2019 – 10:11 a.m.
Session: Androgens – e-Poster session 10
Session Time: 10:05 a.m. – 10:30 a.m. Eastern Time
Location: OMNI Nashville Hotel, Nashville, Tennessee 
About SMSNA

Disclaimer & Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.